The real potential for orphan drug pharma marketing

With drug pipelines moving from essential products to niche therapies, large pharma companies are increasingly attracted to the prospective high demand and low competition of orphan drug markets. However, the ‘sales and marketing’ models for orphan drugs are distinctly different to conventional models for common medications. So the transition to this specialist field is a lot more challenging than it appears.

A new report from FirstWord Dossier – Effective Sales and Marketing Strategies for Orphan Drugs – examines the effectiveness of strategic business models that big pharma are using to market these products. It draws upon the in-depth opinions of 13 experts from the orphan drugs industry, patient organisations, and regulatory authorities in rare diseases.





Report Overview


Effective Sales and Marketing Strategies for Orphan Drugs summarises the main issues, challenges and tactics involved in launching new pharma products for rare diseases. The report compares the critical differences between marketing orphan vs non-orphan drugs – from initial drug development through to commercialisation. It also discusses the huge potential of this field and the key factors driving new product awareness and approval.




Key Report Features
Overview of pharma’s current role in the rare diseases market
Orphan drug business models: specialist biotech vs big pharma
Distinct differences in orphan drug marketing vs common drugs
Clinical and medical challenges in developing orphan drugs
Practical ways to gain valuable patient organisation support
Rare disease indication strategies to maximise commercial return
Benefits of Managed Access Programmes (MAPS) for drug developers
Case studies of various pharma companies’ orphan drug launches




Key Benefits

Review the evolving rare diseases marketplace
Identify the potential of different business models
Manage the challenges specific to orphan drug marketing
Recognise the key factors that influence commercial success
Assess the pharmacoeconomic benefits of orphan drugs
Build key stakeholder alliances across the entire drug lifecycle
Use social media and websites as marketing tools

Key Questions Answered
How do orphan drug business models differ from standard models?
What are the US and European incentives for orphan drug development?
What strategies did GSK use to enter the rare diseases market?
Which issues should you consider before orphan drug investment?
How can you initiate and encourage corporate-patient collaborations?
Can an orphan drug ever become a blockbuster?
What can MAPs offer orphan drug developers?
How can you effectively target physicians about rare diseases?

Who Would Benefit From This Report?
This report will be of value to pharma directors and managers with responsibilities in the following areas:

Market access
Marketing management
Business development
Brand marketing
Sales management
Pharmacoeconomics
Clinical research development
Corporate communications
Key Opinion Leader Liaison teams
Patient Advocacy Liaison teams
Medical affairs
This report will also benefit patient group organisations and charities, as well as healthcare legislators and health policy researchers.


Expert Views Include:

Robert Derham, Founder of CheckOrphan
Abdul Mullick, Head of Global Marketing, Genetic Diseases, Genzyme
Craig Kephart, President, CEO of Centric Health Resources
Marc Dunoyer, Head of Rare Diseases Unit, GlaxoSmithKline
Steve Aselage, Executive VP and Chief Business Officer, BioMarin
Dirk Moritz, VP Global Strategic Marketing, Shire Human Genetic Therapies
Stephen C. Groft, Director, Office of Rare Diseases, National Institutes of Health
Hans Schikan, Chief Executive Officer of Prosensa
Nick Sireau, Chairman of the AKU Society
Simon Estcourt, Senior VP Strategy and Corporate, Idis
Maryze Schoneveld van der Linde, founder of Patient Centered Solution
Theresa Heggie, Senior VP of Global Commercial Operations, Shire Human Genetic Therapies
Tony Hall, Chief Medical Officer at PSR


Key Quotes

“If you’re not doing the pre-marketing activity for orphan drug launches you’re going to fail. It will cost you a lot more and you’re not going to have a real defined patient population,” – Robert Derham, founder of CheckOrphan.

“There’s an advantage to being first in your orphan drug market if you do it right. Other products may seem to work as well but the difference is in your programme,” – Craig Kephart, CEO of Centric Health Resources.

“Some big pharma are trying to make a business out of orphans but this isn’t something that comes naturally to them…they have to change their mind set to go into a market like this,” – Steve Aselage, executive VP, BioMarin.

Orphan drugs appear superficially as a very lucrative space: rare diseases, few competitors …but this takes time and persistence,” – Abdul Mullick, head of global marketing, genetic diseases, Genzyme.

“More than any other area, the advocacy that patient organisations bring to this area is really important, and these relationships start very early in drug development,” – Theresa Heggie, senior VP, global commercial operations, Shire Human Genetic Therapies


Table Of Contents

Executive summary
Methodology
Introduction
> Legislation and incentives
> The rare diseases market
> Orphan drug indications
> Patient focus
How do pre-marketing development strategies contribute towards later commercial success?
Is the potential of the orphan drug market enough to attract investment?
Regulations and incentives
> Market exclusivity in the EU
> Protocol assistance
> Fee reductions
> EU-funded research
> Orphan drug centralized procedure at European level
Evolution of the orphan drug market
> Development of drugs for rare diseases compared to drugs for more common diseases
> Optimizing the orphan drug networks to maximize commercial return
> Orphan drug business models: specialist biotech versus big pharma
What are the major challenges to the orphan drug development process and business model?
> Medical and clinical challenges to orphan drug development
> Diagnosis
> Disease understanding
> Case study 1: Fabry Outcome Survey
> Clinical trial challenges
> Case study 2:
Endpoints stall AKU clinical trial
Aspects of the orphan drug business model that may benefit from change
> Harmonization of clinical trial processes between the EU and US
> Pricing and reimbursement
> Openness between pharma and patients
‘Sales and marketing’ strategy: will an orphan drug ever become a blockbuster?
> Optimizing the company-physician relationship in the orphan drug space
> Case study 3: Prolastin - An integrated healthcare management model of sales and marketing
> Disease and product familiarization amongst physicians and patients
> Diagnosis
> ‘Sales and marketing’ infrastructures
> Targeting physicians in rare diseases
> Competition in the orphan drug market
> Social media in communications and the marketing mix
Rare disease indication strategies
> New molecular entity (NME) for unmet medical need
> Drug for a rare disease applied to a common disease
> Re-purposing
How can companies collaborate with patient organizations across the orphan drug lifecycle to the mutual benefit of both?
> Motivated patients and patient organizations
> The interface between patient organizations and industry
> Patient organizations
> EURORDIS and NORD
> Mutual benefits
> Patient Registries
> Natural history registry
> Product registry
> The Global Rare Disease Registry and Data Repository (GRDR)
> European Centres of Expertise and EUROPLAN
> How patients can drive research and drug development in rare diseases
What can Managed Access Programmes offer companies developing orphan drugs?
> When to use a MAP
> Benefits of a Managed Access Programme
> Access to medicines
> Data
> Stakeholder engagement
> Market development
> Market testing pre-approval (between post-Phase III and first submission)
> Ensuring continuity of patient supply
> Access in certain countries post-launch
Regulations and national plans for Managed Access Programmes

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Global Pediatric Drugs and Vaccines Market

Global Pediatric Drugs and Vaccines Market

  • $ 4 950
  • Industry report
  • September 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective ...

Monochloroacetic Acid (MCA) Market for Cellulosics, Agrochemicals, Surfactants, Thioglycolic Acid (TGA) and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Monochloroacetic Acid (MCA) Market for Cellulosics, Agrochemicals, Surfactants, Thioglycolic Acid (TGA) and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • $ 4 795
  • Industry report
  • August 2014
  • by Transparency Market Research

Monochloroacetic acid (MCA) is a halogenated derivative of acetic acid. It is used in the production of a variety of compounds and intermediates. MCA is majorly used in the production of carboxymethyl ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.